
News|Videos|June 23, 2025
Event-free Survival (EFS) in MATTERHORN: A Randomized, Phase 3 Study of Durvalumab plus 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel Chemotherapy (FLOT) in Resectable Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
Author(s)Yelena Y. Janjigian, MD
Presented by Yelena Y. Janjigian at ASCO 2025, the Phase 3 MATTERHORN study demonstrated that adding durvalumab to FLOT significantly improved event-free survival compared with FLOT alone in patients with resectable gastric and gastroesophageal junction adenocarcinoma, with consistent benefit across subgroups and no new safety concerns.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5



































